Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: a rare phenomenon with more challenges for hematologists.

Abstract

Donor cell leukemia (DCL) or Donor cell myelodysplastic syndrome (DC-MDS) is a rare type of leukemia or MDS and originates from the donor cells. It has very low frequency, but it seems to be steadily increasing as the physiopathology and mechanisms remain largely unknown. Here we report one case of acute lymphocytic leukemia (ALL) and one case of MDS of donor origin after allogeneic hematopoietic stem cell transplantation (HSCT). We also collated and reviewed literatures regarding DCL, and discuss the morbidity of DCL, the methods used to confirm donor origin and the etiology and pathogenesis of DCL. A new proposed theory will help us to better understand the mechanism for the oncogenesis of DCL.

• Authors: Suping Zhang, Li Li, Weijie Cao, Yingmei Li, Zhongxing Jiang, Jifeng Yu, Dingming Wan
• Journal: Hematology (Amsterdam, Netherlands) (Hematology) Vol. 26 Issue 1 Pg. 648-651 (Dec 2021) ISSN: 1607-8454 [Electronic] England
• PMID: 34474660 (Publication Type: Case Reports, Journal Article, Video-Audio Media)

Topics

• Adult
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (etiology, therapy)
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (therapy)
• Transplantation Conditioning (adverse effects)